Cdc25a phosphatase inhibitor for use in thetreatment of a drug resistant cancer and/or in the prevention of tumor relapse

The invention relates to a CDC25A phosphatase inhibitor for use in the treatment of drug resistant cancer or for use in the prevention of tumor relapse in a patient suffering or having suffered from cancer. In a preferred embodiment, the drug resistant cancer according to the invention is associated with a mutated FLT3-ITD such as Acute Myeloid Leukemia (AML). Autors demonstrate that inhibiting CDC25A reduces proliferation and induces monocytic differentiation of FLT3-ITD-positive AML cells in vitro and in vivo, and they argue for a central function of this phosphatase in the hematopoietic differentiation arrest of these cells.

Keywords: CDC25A phosphatase inhibitor, AML, FLT3-ITD, antisense oligonucleotide
Patent Application number: EP N° 14 306 492.1
Oncotarget. 2015 Nov 10;6(35):38061-78. doi: 10.18632/oncotarget.5706.



Business Developper
Elodie Acloque
Elodie Acloque
Business Developer
Patent filling date: 24-09-2014

You might also be interested in